These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 19450872)

  • 21. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
    Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
    Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.
    Woelber L; Jung S; Eulenburg C; Mueller V; Schwarz J; Jaenicke F; Mahner S
    Eur J Surg Oncol; 2010 Jun; 36(6):583-8. PubMed ID: 20488646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Secondary cytoreductions in the treatment of ovarian cancers].
    Zylberberg B; Dormont D; Janklewicz S; Daraï E; Madelenat P; Antoine JM
    Gynecol Obstet Fertil; 2000 Feb; 28(2):127-36. PubMed ID: 10758587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery for stage IV epithelial ovarian cancer.
    Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
    J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up.
    Scholz HS; Tasdemir H; Hunlich T; Turnwald W; Both A; Egger H
    Gynecol Oncol; 2007 Sep; 106(3):591-5. PubMed ID: 17619055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recurrent epithelial ovarian cancer].
    Ding X; Lang J; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Carbone A
    Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
    Vaccarello L; Rubin SC; Vlamis V; Wong G; Jones WB; Lewis JL; Hoskins WJ
    Gynecol Oncol; 1995 Apr; 57(1):61-5. PubMed ID: 7705701
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
    Benedetti Panici P; De Vivo A; Bellati F; Manci N; Perniola G; Basile S; Muzii L; Angioli R
    Ann Surg Oncol; 2007 Mar; 14(3):1136-42. PubMed ID: 17195909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer.
    Everett EN; French AE; Stone RL; Pastore LM; Jazaeri AA; Andersen WA; Taylor PT
    Am J Obstet Gynecol; 2006 Aug; 195(2):568-74; discussion 574-6. PubMed ID: 16890558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.
    Munkarah AR; Coleman RL
    Gynecol Oncol; 2004 Nov; 95(2):273-80. PubMed ID: 15491746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma].
    Wu M; Shen K; Lang JH; Huang RL; Huang HF; Pan LY
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1406-9. PubMed ID: 16029654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):136-41. PubMed ID: 15790449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage cytoreductive surgery for recurrent endometrial cancer.
    Bristow RE; Santillan A; Zahurak ML; Gardner GJ; Giuntoli RL; Armstrong DK
    Gynecol Oncol; 2006 Oct; 103(1):281-7. PubMed ID: 16631236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 63.